跳至主要内容
临床试验/NCT01459575
NCT01459575已完成不适用

Unboosted Atazanavir as Initial ART Therapy in China

National Center for AIDS/STD Control and Prevention, China CDC1 个研究点 分布在 1 个国家开始时间: 2005年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
试验地点
1

研究概览

简要总结

This is an open-label, Pilot study.The study hypothesis is that the feasibility and efficacy of a non-boosted ATV based HAART will be well as the first line treatment in a Chinese resource-limited setting.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed written informed consent
  • The subject should have established HIV infection more than 6 month.
  • Qualifying plasma HIV RNA ≥ 2,000 c/mL and a CD4 cell count within 100 - 350 cells/mm3
  • ≥16 years of age
  • Both females of child-bearing potential and males must utilize effective barrier contraception - other contraception in addition to barrier methods are permitted
  • Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study in such a manner that the risk of pregnancy is minimized.

排除标准

  • Patients who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study.
  • Presence of a newly diagnosed HIV-related opportunistic infection or any medical condition requiring acute therapy at the time of enrollment.
  • History of hemophilia
  • Proven or suspected acute hepatitis in the 30 days prior to study entry. Subjects with chronic hepatitis are eligible provided that their liver function enzymes are < 3 times the upper limit of normal.
  • Presence of cardiomyopathy.
  • A history of arrhythmia or clinical symptoms potentially related to heart block or second / third degree heart block.
  • Inability to tolerate oral medication
  • Presence of a newly diagnosed HIV-related opportunistic infection or any medical condition requiring acute therapy at the time of enrollment.

研究者

发起方
National Center for AIDS/STD Control and Prevention, China CDC
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

NCAIDS

National Center for AIDS/STD Control and Prevention

National Center for AIDS/STD Control and Prevention, China CDC

研究点 (1)

Loading locations...

相似试验